Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 10/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 3/20 | 0.40 |
| ▸ | DRD4 | P21917 | 3/20 | 0.40 |
| ▸ | DRD3 | P35462 | 3/20 | 0.40 |
| ▸ | JAK3 | P52333 | 2/20 | 0.40 |
| ▸ | DTYMK | P23919 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.40 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30509700 | 1.00 | HSD11B1 (0.42) | HSD11B1POLBDRD2DRD4DRD3 | |
| SCHEMBL25307353 | 0.86 | CYP11B2 (0.38) | HSD11B1POLBDRD2DRD4DRD3 | |
| SCHEMBL30509709 | 0.85 | CYP11B2 (0.39) | HSD11B1POLBDRD2DRD4DRD3 | |
| SCHEMBL25426035 | 0.85 | CYP11B2 (0.39) | HSD11B1POLBDRD2DRD4DRD3 | |
| SCHEMBL25866544 | 0.82 | MAP2K1 (0.39) | HSD11B1POLBDRD2DRD4DRD3 | |
| SCHEMBL25427796 | 0.81 | HSD11B1 (0.41) | HSD11B1POLBJAK3DTYMKMAP2K1 | |
| SCHEMBL30509712 | 0.81 | HSD11B1 (0.41) | HSD11B1POLBJAK3DTYMKMAP2K1 | |
| SCHEMBL30509683 | 0.81 | HSD11B1 (0.42) | HSD11B1POLBJAK3DTYMKMAP2K1 | |
| SCHEMBL25428242 | 0.81 | HSD11B1 (0.42) | HSD11B1POLBJAK3DTYMKMAP2K1 | |
| SCHEMBL7470277 | 0.79 | GPR119 (0.46) | POLBDTYMKCYP11B2MKNK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023141225-A1 | FUSED HETEROCYCLES AS 5-HT2A RECEPTOR AGONISTS | ONSERO THERAPEUTICS INC. (US) | 2023-07-27 | — | — | WO | disclosed |
| WO-2023141225-A1 | FUSED HETEROCYCLES AS 5-HT2A RECEPTOR AGONISTS | ONSERO THERAPEUTICS INC. (US) | 2023-07-27 | — | — | WO | disclosed |